Leucine‐rich alpha‐2 glycoprotein (LRG), which was approved in Japan since June 2020, is attracting attention as a serum biomarker that can predict endoscopic activity in patients with inflammatory bowel disease (IBD).3 Here, LRG1 is linked to inflammatory bowel disease.